Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

New treatment regimen for hepatitis C in transplant patients produces promising results

New treatment regimen for hepatitis C in transplant patients produces promising results

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

FDA approves new hepatitis C drug, Harvoni

FDA approves new hepatitis C drug, Harvoni

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

Gilead to boost price of new hepatitis c drug

Gilead to boost price of new hepatitis c drug

Researchers examine whether new drug offers added benefit for patients with chronic HCV

Researchers examine whether new drug offers added benefit for patients with chronic HCV

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

New study in recognition of World Hepatitis Day released on Life Sciences Connect

New study in recognition of World Hepatitis Day released on Life Sciences Connect

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

Drug industry news: FDA again offers warning about a Dallas compounding pharmacy; more on Sovaldi

Drug industry news: FDA again offers warning about a Dallas compounding pharmacy; more on Sovaldi

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

Merck enters into definitive agreement with Idenix

Merck enters into definitive agreement with Idenix

Biomedical scientists explore mechanisms of novel treatments for HCV

Biomedical scientists explore mechanisms of novel treatments for HCV

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection